- Prior treatment with any systemic cancer immunotherapy (including, but not limited to anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, anti-CD137 antibodies, anti-OX-40 antibodies, anti-CD40 antibodies, interferon [IFN]-alpha, interleukin [IL]-2, therapeutic anticancer vaccines, bone marrow transplantation, cellular immunotherapies including chimeric antigen receptor-modified T cells, or bi-specific CD3 antibodies), or prior allogeneic bone marrow transplantation, or prior solid organ transplantation